Karyopharm Therapeutics Inc., a pharmaceutical company focused on developing drugs that fight nuclear export in cancer and other diseases, is making strides in the medical community. The company has developed Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit protein exportin 1 (XPO1). Its lead compound, XPOVIO, has demonstrated successful results in combination with bortezomib and dexamethasone for multiple myeloma treatment, as well as in relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL) treatment. Moreover, Karyopharm is working on Selinexor, ELTANEXOR, verdinexor, KPT-9274, and IL-12 compounds to treat multiple myeloma, endometrial cancer, myelofibrosis, DLBCL, and Myelodysplastic Neoplasms. Through the license agreement with Menarini Group and Antengene Therapeutics, Karyopharm seeks to commercialize its drugs for human oncology indications. Additionally, the commercialization of XPOVIO is undertaken in partnership with FORUS Therapeutics. Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm Therapeutics is well on its way to developing innovative treatments for the most challenging diseases.
Karyopharm Therapeutics's ticker is KPTI
The company's shares trade on the NASDAQ stock exchange
They are based in Newton, Massachusetts
There are 51-200 employees working at Karyopharm Therapeutics
It is karyopharm.com
Karyopharm Therapeutics is in the Healthcare sector
Karyopharm Therapeutics is in the Drugs - Generic industry
The following five companies are Karyopharm Therapeutics's industry peers: